Trial Profile
Multicenter, Open-Label Study to Assess the Effects of Certolizumab Pegol on the Reduction of Anterior Uveitis Flares in Axial Spondyloarthritis Subjects With a History of Anterior Uveitis (C-VIEW)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 02 Jan 2024
Price :
$35
*
At a glance
- Drugs Certolizumab pegol (Primary)
- Indications Ankylosing spondylitis; Anterior uveitis; Axial spondyloarthritis
- Focus Therapeutic Use
- Acronyms C-VIEW
- Sponsors UCB Biopharma
- 15 Nov 2023 Results assessing efficacy certolizumab pegol (CZP) compared with standard non-biologic care, presented at the ACR Convergence 2023.
- 05 Jun 2021 Results assessing the 2-year outcomes and impact of certolizumab pegol treatment on acute anterior uveitis in patients with active ankylosing spondylitis, presented at the 22nd Annual Congress of the European League Against Rheumatism.
- 01 Jun 2021 According to an UCB Media Release, results from a post hoc analysis of this trial will be presented at the European Congress of Rheumatology (EULAR) 2021.